key: cord-0264503-8zsdbiwg
authors: Yang, Y.; Yang, M.; Peng, Y.; Liang, Y.; Wei, J.; Xing, L.; Guo, L.; Li, X.; Li, J.; Wang, J.; Li, M.; Xu, Z.; Zhang, M.; Wang, F.; Shi, Y.; Yuan, J.; Liu, Y.
title: Persistent while declined neutralizing antibody responses in the convalescents of COVID-19 across clinical spectrum during the 16 months follow up
date: 2021-09-26
journal: nan
DOI: 10.1101/2021.09.18.21263550
sha: 9fcb1d24ca706aa4d3b8af1de0509abd13f638cb
doc_id: 264503
cord_uid: 8zsdbiwg

Elucidation the kinetics of neutralizing antibody response in the coronavirus disease 2019 (COVID-19) convalescents is crucial for the future control of the COVID-19 pandemic and vaccination strategies. Here we tested 411 sequential plasma samples collected up to 480 days post symptoms onset (d.a.o) from 214 convalescents of COVID-19 across clinical spectrum without re-exposure history after recovery and vaccination of SARS-CoV-2, using authentic SARS-CoV-2 microneutralization (MN) assays. COVID-19 convalescents free of re-exposure and vaccination could maintain relatively stable anti-RBD IgG and MN titers during 400~480 d.a.o after the peak at around 120 d.a.o and the subsequent decrease. Undetectable neutralizing activity started to occur in mild and asymptomatic infections during 330 to 480 d.a.o with an overall rate of 14.29% and up to 50% for the asymptomatic infections. Significant decline in MN titers was found in 91.67% COVID-19 convalescents with [≥] 50% decrease in MN titers when comparing the available peak and current MN titers ([≥] 300 d.a.o). Antibody-dependent immunity could also provide protection against most of circulating variants after one year, while significantly decreased neutralizing activities against the Beta, Delta and Lambda variants were found in most of individuals. In summary, our results indicated that neutralizing antibody responses could last at least 480 days in most COVID-19 convalescents despite of the obvious decline of neutralizing activity, while the up to 50% undetectable neutralizing activity in the asymptomatic infections is of great concern.

Introduction 44 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh 45 member of coronaviruses that has been found to infect human beings in late 46 December, 2019, in Wuhan, China 1,2 . The pandemic of SARS-CoV-2 is ongoing and 47 has caused over 209 million human infections with over 4.4 million fatal cases 48 worldwide until now (https://covid19.who.int/). Notably, asymptomatic infections 49 account for up to 40% of all the SARS-CoV-2 infections, and silent transmission 50 during the pre-symptomatic and asymptomatic stages are responsible for more than 51 50% of the overall attack rate in COVID-19 outbreaks 3-6 . Therefore, 52 antibody-mediated protective immunity induced either by natural infection or 53 vaccination is of great importance for the control of COVID-19 pandemic. 54 Neutralizing antibodies (NAbs) rapidly rise after infection and maintained for 55 years to decades by long-lived plasma and memory B cells in most acute viral 56 infections, playing vital roles in the viral clearance and protection against viral 57 diseases 7 . Studies have shown that the antibody response induced by coronavirus in 58 human beings tends to wane over time, and varies among types of coronaviruses and 59 the severity of the disease 8 . Seasonal human coronaviruses including HCoV-229E, 60 HCoVOC43, HCoV-NL63, and HCoV-HKU1 induce short-lasting antibody response, 61 and reinfection with the same seasonal coronavirus occurred frequently at 12 months 62 after infection 9 . However, the two coronavirus that cause severe disease in human 63 beings including SARS-CoV and Middle East Respiratory Syndrome coronavirus 64 (MERS-CoV) induce stronger and more durable antibody responses up to 3 years 8,10-14 . 65 Recent data from animal models, therapeutic use of neutralizing monoclonal 66 antibodies and convalescent plasma suggest the critical role of neutralizing antibody 67 in controlling SARS-CoV-2 infection and reinfection [15] [16] [17] [18] [19] [20] [21] [22] , while a key question yet to 68 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 be addressed is whether COVID-19 convalescents could maintain long-lasting 69 antibody mediated protective immunity. Studies is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 oxygen partial pressure (PaO2) / fraction of inspired oxygen (FiO2) ≤ 300 mmHg (1 115 mmHg = 0.133 kPa). Laboratory confirmed patients who had any of the following 116 were considered critically ill: 1) respiratory failure requiring mechanical ventilation, 2) 117 shock, or 3) failure of other organs requiring intensive care unit (ICU). The 118 asymptomatic cases were defined as previously reported 34 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 reported with some modification 39 . Serum samples were heat-inactivated at 56°C for 140 30 min to remove complement activity, and then diluted in white, flat-bottom 96-well 141 plates (Thermo Fisher) with a dilution of 1 in 10 with a total volume of 50μl. Then 142 200 TCID50 of SARS-CoV-2 pseudotyped particles in 50 μl were added to each well 143 and incubated at 37°C for 1h. A total of 4 × 10 5 ACE2-293T cells (Vazyme) in 100μl 144 complete media were added per well and incubated for 48h at 37°C and 5% CO2. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.18.21263550 doi: medRxiv preprint 1:100 in 5% BSA was added to the high-binding ELISA plates (Corning) pre-coated 165 with antigen (N protein or RBD) and incubated for 2 h at room temperature. Wells 166 were then washed with PBS-T (PBS with 0.05% Tween-20), and secondary antibody 167 was added and incubated for 1 h at room temperature. After another three washes with 168 PBST, tetramethylben zidine (TMB) substrate (Sangon Biotech) was added at room 169 temperature in the dark. After 15 minutes, the reaction was stopped with a 2M H2SO4 170 solution and then the absorbance was measured at 450 nm. A serum sample is 171 considered positive when the OD is fourfold above background. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.18.21263550 doi: medRxiv preprint

Baseline characteristics of the cohort 183 A total of 214 laboratory confirmed COVID-19 patients with 51 individuals in severe 184 group, 134 individuals in mild group and 29 individuals in asymptomatic group were 185 included in this study for the analysis of antibody response. This cohort was 46.73% 186 male with an average age of 48 years (range 2-79) ( Table 1) , and patients in severe 187 group were significantly older than mild and asymptomatic groups. The body mass 188 index (BMI) in severe group was significantly higher than the asymptomatic group. 189 The median days of interval between onset to qPCR negative for SARS-CoV-2 was is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. mild groups showed no statistical significance, while both significantly higher than 244 the asymptomatic group. In detail, peak MN titers for the severe group were all ≥ 80, 245 and 50% belonged to range of 640-5120. For the mild group, peak MN titers varied 246 from 10 to 1280, and 26.06% belonged to range of 640-5120. While for the 247 asymptomatic group, all peak MN titers were ≤ 160, and 81,82% belonged to range of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10. 1101 /2021 To obtain an overall kinetics of antibody response in COVID-19 convalescents, the 257 anti-RBD IgG and MN titers of the 411 plasma samples from 214 were tested and 258 analyzed as a whole, and also stratified into severe, mild and asymptomatic groups. 259 Generally, both the anti-RBD IgG and MN titers reached the peak at around 120 days is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.18.21263550 doi: medRxiv preprint current/peak was 46.38% (range: 13.07%~91.99%) ( Figure 3C and 3E). Similar 282 pattern was found for the MN titers ( Figure 3D, 3E and 3F) . A significant waning of 283 MN titers was also found in the last follow up for 91.67% COVID-19 convalescents 284 with ≥ 50% decrease in MN titers. Notably, stable MN titers were also found in 8.33% is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figure 1C ). Of concern, none of 320 them were from the severe group, and the rate for the asymptomatic group reached 321 50% ( Figure 1C Figure 3F ). These data indicated that despite of significant decline in neutralizing 331 antibody response, it could also be maintained at least 480 days in most of the 332 COVID-19 convalescents, while the up to 50% undetectable neutralizing activity in 333 the asymptomatic infections is of great concern. Of note, the decline in neutralizing 334 activity was consistent with the decline in anti-RBD IgG antibody ( Figure 3E ). Given 335 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.18.21263550 doi: medRxiv preprint the high coincidence rate (93.19%) and correlation between levels of anti-RBD IgG 336 and the MN titers ( Figure 1E and 1F is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. 377 Although reinfection occurred in COVID-19 convalescents or vaccinees, 378 symptomatic reinfections and severe diseases occurred at a lower rate than primary 379 infections 45, 46, 48, 66 . Accordingly, it is of concern that whether COVID-19 380 convalescents need to receive vaccination and when, and also whether the former is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Engl J Med 384, 229-237, doi:10.1056 229-237, doi:10. /NEJMoa2029849 (2021 

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Yang, Y. et al. Development of a reverse transcription quantitative polymerase chain 513 reaction-based assay for broad coverage detection of African and Asian Zika virus lineages.

Virol Sin 32, 199-206, doi:10.1007/s12250-017-3958-y (2017 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 26, 2021. 

ALB (g/dl)

IL-6 (pg/ml) 9

EClinicalMedicine 38, 101018, doi:10.1016/j.eclinm.2021.101018 (2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.18.21263550 doi: medRxiv preprint 657 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 26, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021